Belite Bio’s Post

View organization page for Belite Bio, graphic

992 followers

🧬At our recent event, we showcased additional Stargardt disease Phase 2 results that shows the potential of Tinlarebant to slow or halt lesion growth. In the 24-month study, 42% of patients with ABCA4 mutations saw no new atrophic lesions and maintained stable QDAF levels. #Tinlarebant #StargardtDisease https://lnkd.in/gf_8ny_W

  • No alternative text description for this image

Any time line for launch of drug in market for patients..??

Like
Reply

To view or add a comment, sign in

Explore topics